Skip to main content

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

NEW YORK (

TheStreet

) --

Regeneron Pharmaceuticals

(Nasdaq:

REGN

) hit a new 52-week high Tuesday as it is currently trading at $147.34, above its previous 52-week high of $146.37 with 366,313 shares traded as of 1:25 p.m. ET. Average volume has been 902,500 shares over the past 30 days.

Regeneron has a market cap of $13.63 billion and is part of the

health care

sector and

drugs

industry. Shares are up 162.5% year to date as of the close of trading on Monday.

TheStreet Recommends

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of serious medical conditions in the United States.

  • ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!

TheStreet Ratings rates Regeneron as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, compelling growth in net income, impressive record of earnings per share growth and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company shows weak operating cash flow. You can view the full

Regeneron Ratings Report

.

See all

52-week high stocks

or get investment ideas from our

investment research center

.

null